Miragen Therapeutics Inc (OQ:MGEN)

Business Focus: Biotechnology & Medical Research

Sep 14, 2020 05:00 pm ET
miRagen Announces Leadership Transition and Review of Strategic Alternatives 
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that its Board of Directors has appointed Lee Rauch, the Company’s current...
Aug 20, 2020 04:05 pm ET
miRagen Announces Results of Meeting With FDA Regarding the Design of Pivotal Trial for Cobomarsen in ATLL
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced that the company held a Type C...
Aug 05, 2020 04:05 pm ET
miRagen Reports Second Quarter 2020 Financial Results and Provides Business Updates
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary RNA-targeted therapies with a specific focus on microRNAs, today reported financial results for the second...
Aug 04, 2020 08:00 am ET
miRagen to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that William S. Marshall, Ph.D., President and Chief Executive Officer of...
Jul 28, 2020 08:00 am ET
miRagen, Investigators from Goethe University and University Hospital Frankfurt and Servier Publish MRG-110 Phase 1 Pharmacodynamic Biomarker Data in Nucleic Acid Therapeutics
Goethe University, University Hospital Frankfurt and miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that preliminary results...
Jul 24, 2020 09:31 am ET
Thinking about buying stock in Miragen Therapeutics, ChannelAdvisor, Northern Dynasty Minerals, Tiziana Life Sciences, or Tonix Pharmaceuticals?
NEW YORK, July 24, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MGEN, ECOM, NAK, TLSA, and TNXP....
Jul 23, 2020 04:32 pm ET
Cobomarsen Receives Orphan Drug Designation From the U.S. FDA for the Treatment of T-cell Lymphoma
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the Food & Drug Administration (FDA) has granted orphan drug designation...
Jul 22, 2020 08:00 am ET
miRagen to Report Second Quarter 2020 Financial Results on August 5, 2020
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced it will report its second quarter 2020 financial results after the financial...
Jul 21, 2020 09:31 am ET
Thinking about buying stock in New Age Beverages, Lexicon Pharmaceuticals, Miragen Therapeutics, Opko Health, or Niu Technologies?
NEW YORK, July 21, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NBEV, LXRX, MGEN, OPK, and NIU....
Jul 02, 2020 04:15 pm ET
miRagen Regains Compliance With Nasdaq Listing Requirements
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that on July 1, 2020 it received written notice from the Nasdaq Listing...
Jun 22, 2020 05:08 pm ET
miRagen Announces Encouraging Preclinical Safety and Efficacy Data for its Next-generation miR-29 Replacement Product Candidate Intended for the Treatment of Idiopathic Pulmonary Fibrosis
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced preclinical safety and efficacy data for MRG-229, a next-generation miR-29...
Jun 22, 2020 09:31 am ET
Thinking about buying stock in Virgin Galactic, Miragen Therapeutics, Nantkwest Inc, Agenus Inc, or Norwegian Cruise Line?
NEW YORK, June 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SPCE, MGEN, NK, AGEN, and NCLH....
Jun 18, 2020 04:05 pm ET
miRagen Strengthens Leadership Team with Appointment of Lee Rauch as Chief Operating Officer
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the appointment of Lee Rauch as Chief Operating Officer, effective...
Jun 17, 2020 09:31 am ET
Thinking about buying stock in Energous Corp, Miragen Therapeutics, Hertz, Kopin Corp, or MGM Resorts?
NEW YORK, June 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WATT, MGEN, HTZ, KOPN, and MGM....
Jun 16, 2020 04:01 pm ET
miRagen to Host a Key Opinion Leader Call on Idiopathic Pulmonary Fibrosis on Tuesday, June 23rd
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced it is scheduled to host a key opinion leaders (KOL) call regarding idiopathic...
May 26, 2020 08:00 am ET
miRagen to Present at the Jefferies 2020 Virtual Global Healthcare Conference
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that William S. Marshall, Ph.D., President and Chief Executive Officer of...
May 07, 2020 04:05 pm ET
miRagen Reports First Quarter 2020 Financial Results and Provides Corporate Update
miRagen Therapeutics, Inc. (NASDAQ: MGEN), today provided operational highlights and financial results for the first quarter ended March 31, 2020. “We entered 2020 with streamlined operations and a team focused on delivering several important...
Apr 23, 2020 08:00 am ET
miRagen Therapeutics to Report First Quarter 2020 Financial Results On May 7, 2020
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced it will report its first quarter 2020 financial results after the financial...
Mar 11, 2020 04:05 pm ET
miRagen Reports Fourth Quarter and Full Year 2019 Financial Results
miRagen Therapeutics, Inc. (NASDAQ: MGEN), today reported operating highlights and financial results for the quarter and full-year ended December 31, 2019 and provided an outlook for 2020. “In 2019, we announced a series of changes intended to...
Feb 20, 2020 08:00 am ET
miRagen Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on March 11, 2020
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced it will report its fourth quarter and full year 2019 financial results after...
Feb 07, 2020 09:00 am ET
miRagen Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants to Purchase Common Stock
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the pricing of an underwritten public offering of 15,000,000 shares of its...
Feb 06, 2020 04:03 pm ET
miRagen Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it intends to offer for sale shares of its common stock and warrants to...
Jan 30, 2020 07:00 am ET
miRagen Therapeutics Announces Positive Data for Cobomarsen in Adult T-Cell Leukemia/lymphoma Patients With Residual Disease
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced new efficacy and safety data from the ATLL arm of its ongoing...
Jan 23, 2020 08:00 am ET
miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma at Two Upcoming Conferences
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced that it will present new efficacy and safety data from its Phase...
Dec 11, 2019 04:05 pm ET
miRagen Announces Major Changes to Company’s Strategy
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced a series of strategic changes across its business that are...
Nov 26, 2019 08:00 am ET
miRagen to Present at the Evercore ISI HealthCONx Conference 2019
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced that management will be presenting at the Evercore ISI...
Nov 07, 2019 04:01 pm ET
miRagen Reports Third Quarter 2019 Results and Provides Corporate Update
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today reported financial results for the third quarter ended September 30, 2019...
Oct 28, 2019 09:00 am ET
miRagen to Present at the DIA/FDA Oligonucleotide-Based Therapeutics Conference Today
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, will present an overview of its novel second generation miR-29 mimics (MRG-229)...
Oct 22, 2019 08:00 am ET
miRagen Therapeutics to Report Third Quarter 2019 Financial Results and Host a Conference Call
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, will host a conference call and webcast on Thursday, November 7th, at 4:30 p.m....
Oct 16, 2019 02:45 am ET
miRagen Announces New Clinical Data Showing MRG-110 Positively Impacted Tissue Repair and New Blood Vessel Growth
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today new data from two Phase 1 clinical trials of MRG-110, miRagen’s microRNA-92...
Aug 15, 2019 08:00 am ET
miRagen Therapeutics to Present a Corporate Overview at the Robert W. Baird & Co. 2019 Global Healthcare Conference
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, announced today that William S. Marshall, Ph.D., President and Chief Executive...
Aug 12, 2019 08:00 am ET
miRagen Therapeutics to Present a Corporate Overview at the 2019 Wedbush Healthcare Conference
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, announced today that William S. Marshall, Ph.D., President and Chief Executive...
Aug 07, 2019 04:05 pm ET
miRagen Reports Second Quarter 2019 Results; Regains Global Rights to MRG-110 and Announces Corporate Restructuring
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today reported financial results for the second quarter ended June 30, 2019 and...
Jul 24, 2019 08:00 am ET
Miragen Therapeutics to Report Second Quarter 2019 Financial Results and Host a Conference Call on August 7th
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, will host a conference call on Wednesday, August 7th, at 4:30 p.m. ET to discuss...
May 28, 2019 04:30 pm ET
miRagen Therapeutics to Present a Corporate Overview at the Jefferies 2019 Global Healthcare Conference
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, announced today that William S. Marshall, Ph.D., President and Chief Executive...
May 21, 2019 07:00 am ET
miRagen Presents Preclinical Data in Pulmonary Fibrosis Using Second Generation microRNA-29 Replacement Product Candidate at the 2019 American Thoracic Society International Conference
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that it will report new data demonstrating that systemic administration of its...
May 08, 2019 04:01 pm ET
miRagen Announces First Quarter 2019 Financial Results and Provides Corporate Update
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today reported financial results for the first quarter ended March 31, 2019 and...
Apr 29, 2019 07:00 am ET
miRagen Therapeutics Announces New Data Supporting the Potential Use of Remlarsen to Prevent Corneal Fibrosis at the 2019 ARVO Meeting
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced data from a preclinical study of remlarsen, a microRNA-29 replacement,...
Apr 26, 2019 07:00 am ET
miRagen Announces New Clinical Data for Cobomarsen in ATLL Patients at the 19th Annual HTLV Congress in Lima, Peru
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced incremental new data from its Phase 1 clinical trial evaluating the safety,...
Apr 25, 2019 08:00 am ET
miRagen Therapeutics to Report First Quarter 2019 Financial Results and Host a Conference Call on May 8th
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will host a conference call on Wednesday, May 8th, at 4:30 p.m. ET to discuss its financial...
Mar 13, 2019 04:05 pm ET
miRagen Announces Fourth Quarter and Full Year 2018 Financial Results and Provides 2019 Outlook
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today reported financial and operating results for the fourth quarter and...
Mar 06, 2019 08:00 am ET
miRagen Therapeutics to Present a Corporate Overview at the 29th Annual Oppenheimer & Co. Healthcare Conference
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that William S. Marshall, Ph.D., President and Chief Executive Officer, will...
Feb 20, 2019 08:00 am ET
miRagen Therapeutics to Report Fourth Quarter and Fiscal 2018 Financial Results and Host a Conference Call on March 13th
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will host a conference call on Wednesday, March 13, at 4:30 p.m. ET to discuss its financial...
Jan 10, 2019 07:00 am ET
miRagen Announces New Clinical Data in Patients With Three Different Types of Blood Cancers Treated With Cobomarsen
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced data from its Phase 1 clinical trial evaluating the safety, tolerability and...
Dec 20, 2018 07:00 am ET
miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma and Cutaneous T-Cell Lymphoma at the 11th Annual T-Cell Lymphoma Forum
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it will present new data from its Phase 1 trial of cobomarsen in HTLV-1...
Dec 05, 2018 04:05 pm ET
miRagen Therapeutics Announces Board of Director Evolution and Appointment of New Chairman
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the appointment of Jeff Hatfield, a Director since 2017, as Chairman of the...
Dec 02, 2018 05:00 pm ET
miRagen Therapeutics Announces Final Safety, Biodistribution and Clinical Efficacy Data From Phase 1 Cobomarsen Clinical Trial in Patients With Mycosis Fungoides
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced data from its Phase 1 clinical trial evaluating the safety, tolerability,...
Nov 07, 2018 04:01 pm ET
miRagen Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today reported third quarter 2018 financial results and provided a corporate update. “We had...
Nov 01, 2018 09:00 am ET
Miragen Therapeutics to Present New Cobomarsen Phase 1 Clinical Trial Data at the 2018 American Society of Hematology Annual Meeting
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that new data from its Phase 1 trial of cobomarsen, an inhibitor of miR-155,...
Oct 29, 2018 07:00 am ET
miRagen Therapeutics to Present at two Investor Conferences in November 2018
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that William S. Marshall, Ph.D., President and Chief Executive Officer, is...
Oct 24, 2018 07:00 am ET
miRagen Therapeutics to Report Third Quarter 2018 Financial Results and Host Conference Call on November 7, 2018
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will host a conference call on Wednesday, November 7, 2018, at 4:30 p.m. ET to discuss its...
Oct 01, 2018 07:00 am ET
miRagen Therapeutics Announces the Presentation of Data From Preclinical Studies Demonstrating the Potential Anti-Fibrotic Effect of Remlarsen in the Cornea at the 2018 OLIGO Meeting in Seattle, WA
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced data from its preclinical study of remlarsen, a microRNA-29 replacement,...
Aug 07, 2018 04:05 pm ET
miRagen Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today reported second quarter 2018 financial results and provided a corporate update. “This...
Aug 06, 2018 07:00 am ET
miRagen Therapeutics and The Leukemia & Lymphoma Society® Enter Into an Agreement to Facilitate the Development of Cobomarsen in Cutaneous T-Cell Lymphoma
miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, and The Leukemia Lymphoma Society® (LLS) today announced that they entered into an agreement...
Jul 31, 2018 07:00 am ET
miRagen Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference
miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that William S. Marshall, Ph.D., President and Chief Executive Officer, is...
Jul 25, 2018 07:00 am ET
miRagen Therapeutics to Report Second Quarter 2018 Financial Results and Host Conference Call on August 7, 2018
miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will host a conference call on Tuesday, August 7, 2018, at 4:30 p.m. ET to discuss its...
Jul 10, 2018 07:00 am ET
miRagen Therapeutics Announces Initiation of Phase 2 Clinical Trial of MRG-201
miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the initiation of a Phase 2 clinical trial to evaluate MRG-201 in subjects with...
Jun 04, 2018 07:30 am ET
Miragen Therapeutics to Present First Cobomarsen Phase 1 Clinical Trial Data From Patients With Adult T-Cell Leukemia/lymphoma and New Interim Data From Patients With Mycosis Fungoides at the 2018 Ame
miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced the first observations on the safety and efficacy of cobomarsen in adult T-cell...
May 31, 2018 07:00 am ET
miRagen Therapeutics to Present at Jefferies 2018 Global Healthcare Conference on Thursday, June 7th
miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that William S. Marshall, Ph.D., President and Chief Executive Officer, is...
May 16, 2018 05:00 pm ET
miRagen Therapeutics to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at the 2018 American Society of Clinical Oncology Annual Meeting
miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that new interim data from its ongoing Phase 1 clinical trial of cobomarsen...
May 09, 2018 04:05 pm ET
miRagen Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today reported first quarter 2018 financial results and provided a corporate update. “With...
May 08, 2018 04:05 pm ET
miRagen Therapeutics Announces New Interim Data From Phase 1 Clinical Trial of Cobomarsen in Mycosis Fungoides
miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced new interim data from its Phase 1 clinical trial of cobomarsen in patients with the...
May 02, 2018 04:05 pm ET
miRagen Therapeutics Presents New Preclinical Data Supporting use of MicroRNA-Targeted Therapies for Ophthalmic Diseases
miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announces new data from two preclinical studies investigating microRNA mimics of the...
May 02, 2018 07:00 am ET
miRagen Therapeutics to Report First Quarter 2018 Financial Results and Host Conference Call on May 9, 2018
BOULDER, Colo., May 02, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will host a conference call on Wednesday, May 9, 2018 at 4:30 p.m....
May 01, 2018 07:00 am ET
miRagen Therapeutics Announces Initiation of Second Phase 1 Clinical Trial of MRG-110
BOULDER, Colo., May 01, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the initiation of a second Phase 1 clinical trial of MRG-110...
Apr 30, 2018 04:05 pm ET
miRagen Therapeutics to Participate in Upcoming Investor Conferences
BOULDER, Colo., April 30, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that William S. Marshall, Ph.D., President and Chief Executive Officer, will...
Apr 27, 2018 07:00 am ET
miRagen Therapeutics Announces New Data Showing Administration of MRG-110 Improved Tissue Perfusion and Wound Healing in Late Stage Preclinical Studies
BOULDER, Colo., April 27, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced new data from its preclinical studies of MRG-110, a miR-92 inhibitor, exploring...
Apr 19, 2018 07:00 am ET
miRagen Therapeutics to Present New Preclinical Data at the Wound Healing Society and the Association for Research in Vision and Ophthalmology Annual Meetings
BOULDER, Colo., April 19, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that it will be presenting preclinical data on two of its...
Mar 27, 2018 07:00 am ET
miRagen Announces Initiation of Phase 1 Clinical Trial of MRG-110
BOULDER, Colo., March 27, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today the initiation of a Phase 1 clinical trial of MRG-110 (S95010)...
Mar 14, 2018 04:05 pm ET
miRagen Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
BOULDER, Colo., March 14, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today reported fourth quarter and full year 2017 financial results and provided a...
Mar 07, 2018 07:00 am ET
miRagen Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on March 14, 2018
BOULDER, Colo., March 07, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN) a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will host a conference call on Wednesday, March 14, 2018 at 4:30 p.m....
Mar 05, 2018 07:00 am ET
miRagen Therapeutics to Participate in Upcoming Investor Conferences
BOULDER, Colo., March 05, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN) a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that members of the Company’s management team will provide a company...
Feb 08, 2018 06:45 pm ET
miRagen Therapeutics, Inc. Prices Public Offering of Common Stock
BOULDER, Colo., Feb. 08, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the pricing of its previously announced underwritten public offering of 7,000,000...
Feb 05, 2018 06:05 am ET
miRagen Therapeutics Announces Proposed Public Offering of Common Stock
BOULDER, Colo., Feb. 05, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it intends to offer for sale 7,000,000 shares of its...
Feb 02, 2018 07:00 am ET
miRagen Therapeutics Presents New Data from Phase 1 Clinical Trial of MRG-106 in Mycosis Fungoides at the T-Cell Lymphoma Forum
BOULDER, Colo., Feb. 02, 2018 (GLOBE NEWSWIRE) --  miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced new interim data from its Phase 1 clinical trial of MRG-106 in...
Jan 24, 2018 07:00 am ET
miRagen Therapeutics to Present New MRG-106 Phase 1 Clinical Trial Data at the T-Cell Lymphoma Forum
BOULDER, Colo., Jan. 24, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that new interim results from its ongoing Phase 1 clinical trial...
Jan 05, 2018 07:00 am ET
miRagen Therapeutics Expands Board of Directors with Appointment of Arlene Morris
BOULDER, Colo., Jan. 05, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that it has appointed biotechnology industry veteran Arlene Morris to the...
Dec 11, 2017 04:05 pm ET
miRagen Therapeutics Presents New Interim Clinical Data Expanding on Previous Data Suggesting Positive Impact From Systemically Administered MRG-106 on Mycosis Fungoides Form of Cutaneous T-Cell Lymph
BOULDER, Colo., Dec. 11, 2017 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today new interim results from its ongoing Phase 1 clinical trial of...
Nov 08, 2017 04:05 pm ET
miRagen Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
BOULDER, Colo., Nov. 08, 2017 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced third quarter 2017 financial results and provided a corporate update.
Nov 07, 2017 04:05 pm ET
miRagen Therapeutics to Participate in Four Investor Conferences in November
BOULDER, Colo., Nov. 07, 2017 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN) a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that William S. Marshall, Ph.D., President and Chief Executive Officer, will provide a company overview at the following conferences in November....
Nov 07, 2017 04:05 pm ET
miRagen Therapeutics to Participate in Four Investor Conferences in November
BOULDER, Colo., Nov. 07, 2017 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN) a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that William S. Marshall, Ph.D., President and Chief Executive Officer, will...
Nov 01, 2017 04:05 pm ET
miRagen Therapeutics to Announce Third Quarter 2017 Financial Results and Host Webcast Conference Call on November 8, 2017
BOULDER, Colo., Nov. 01, 2017 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN) will report its third quarter 2017 financial results on Wednesday, November 8, 2017, after the close of the U.S. financial markets. After the announcement, miRagen’s senior management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss its third quarter 2017 financial results and provide a corporate update. The conference call is being webcast and can be accessed from the miRagen website, www.miragen.com, under Investors & Media. A replay of the webcast will be available f...
Nov 01, 2017 09:00 am ET
miRagen Therapeutics to Present New MRG-106 Phase 1 Clinical Trial Data at the 2017 American Society of Hematology Annual Meeting
BOULDER, Colo., Nov. 01, 2017 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that new interim results from its ongoing Phase 1 clinical trial...
Nov 01, 2017 09:00 am ET
miRagen Therapeutics to Present New MRG-106 Phase 1 Clinical Trial Data at the 2017 American Society of Hematology Annual Meeting
BOULDER, Colo., Nov. 01, 2017 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that new interim results from its ongoing Phase 1 clinical trial of MRG-106 in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL) will be presented at the 2017 American Society of Hematology (ASH) Annual Meeting. The meeting is being held December 9-12, 2017 in Atlanta, GA....
Sep 11, 2017 04:05 pm ET
miRagen Therapeutics Presents New MRG-201 Preclinical Data for Inhaled MicroRNA-29 Mimic Targeting Pulmonary Fibrosis
MRG-201 was nebulized and delivered to the lungs via inhalation in rodentsAdministration of aerosolized microRNA-29 mimic was observed to result in down-regulation of pharmacodynamic and mechanistic biomarkers important in fibrotic tissue deposition BOULDER, Colo., Sept. 11, 2017 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today new preclinical safety and feasibility data on inhaled delivery of MRG-201, a microRNA-29 mimic, which miRagen plans to evaluat...
Aug 11, 2017 04:05 pm ET
miRagen Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
New MRG-106 Phase 1 cutaneous T-cell lymphoma clinical trial data releasedExpansion of the MRG-106 trial to include additional potential indicationsTwo new independent members added to its Board of DirectorsConference call and webcast today at 4:30 p.m. ET BOULDER, Colo., Aug. 11, 2017 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced second quarter 2017 financial results and provided a corporate update....
Aug 08, 2017 07:00 am ET
miRagen Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference
BOULDER, Colo., Aug. 08, 2017 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that William S. Marshall, Ph.D., President and Chief Executive Officer, will provide a company overview at the 2017 Wedbush PacGrow Healthcare Conference on Tuesday, August 15, 2017, at 1:20 p.m. ET. The conference is being held at the Le Parker Meridien hotel in New York City....
May 17, 2017 05:05 pm ET
miRagen Therapeutics to Present New Clinical Trial Data for MRG-106, an Oligonucleotide Therapeutic Targeting microRNA-155, at the American Society of Clinical Oncology Annual Meeting
BOULDER, Colo., May 17, 2017 (GLOBE NEWSWIRE) -- Miragen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, announced today that new interim results from its ongoing Phase 1 clinical study of MRG-106 will be presented on June 5, 2017 at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6, 2017 in Chicago, Illinois. ...
May 10, 2017 04:05 pm ET
miRagen Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
 MRG-106 granted orphan-drug status for the treatment of mycosis fungoides by U.S. Food and Drug Administration (FDA)miRagen’s collaboration with Servier extended with the objective to start testing MRG-110 in humans within a year MRG-106 clinical data to be presented at ASCO in June 2017 Cash balance sufficient to fund operations through 2018Conference call today at 4:30 p.m. ET BOULDER, Colo., May 10, 2017 (GLOBE NEWSWIRE) -- Miragen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today ...
May 02, 2017 04:05 pm ET
miRagen Therapeutics to Host Conference Call Discussing First Quarter 2017 Corporate Update and Financial Results
BOULDER, Colo., May 02, 2017 (GLOBE NEWSWIRE) -- Miragen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today announced that it will host a conference call and webcast on Wednesday, May 10, 2017 at 4:30 p.m. ET to discuss a corporate update and financial results for the first quarter 2017....
Mar 31, 2017 04:05 pm ET
miRagen Therapeutics Provides Corporate Update
BOULDER, Colo., March 31, 2017 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (Nasdaq:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today reported recent clinical and financial highlights along with anticipated milestones for 2017....
Feb 13, 2017 04:15 pm ET
miRagen Therapeutics Completes Merger with Signal Genetics and Concurrent $40.7 Million Equity Financing
Merger creates a clinical-stage biopharmaceutical company focused on the discovery and development of select microRNA-targeted therapies ...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.